GlassScriptPhysician profile
Julia Sadlo
NPI 1609632967
$3,106.78
in general payments reported to CMS, 2019-2025
30 companies · $2,240 in 2025
The $2,240 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $867 · 2025: $2,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $350.75 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Novo Nordisk INC | $333.65 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sequel Med Tech, LLC | $222.31 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $204.85 | 2025 | Yorvipath |
| Axsome Therapeutics, INC. | $188.68 | 2024 | Auvelity |
| Insulet Corporation | $179.99 | 2024-2025 | Omnipod |
| Corcept Therapeutics | $175.05 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $167.79 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.28 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $133.50 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $125.94 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Neurocrine Biosciences, INC. | $121.86 | 2025 | |
| Abbott Laboratories | $108.95 | 2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $99.36 | 2024-2025 | Xyosted |
| Lilly USA, LLC | $96.92 | 2024-2025 | Zepbound, Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $58.89 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.32 | 2024-2025 | Jardiance |
| Esperion Therapeutics, INC. | $44.46 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $40.20 | 2025 | |
| Recordati_rare_diseases_inc. | $36.86 | 2025 | Isturisa |
| Rgh Enterprises LLC | $32.90 | 2025 | |
| Chiesi USA, INC. | $29.78 | 2024-2025 | Mycapssa, Juxtapid, Myalept |
| Amgen INC. | $29.70 | 2025 | Tepezza, Repatha |
| Beta Bionics, INC. | $24.94 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Madrigal Pharmaceuticals | $23.88 | 2025 | Rezdiffra |
| Almatica Pharma LLC | $18.09 | 2025 | Loreev Xr |
| Amneal Pharmaceuticals LLC | $17.82 | 2025 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $16.91 | 2025 | |
| Cequr Corporation | $15.40 | 2025 | Cequr Simplicity |
| Dexcom, INC. | $13.75 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Sadlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.